Clinical Trials Logo

Anthrax clinical trials

View clinical trials related to Anthrax.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05672875 Terminated - Anthrax Clinical Trials

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

Start date: January 23, 2023
Phase:
Study type: Observational

This study is intended to estimate the Anthrax LF Dx System specificity. Sensitivity will be estimated with 10% of the samples spiked with recombinant Bacillus anthracis lethal factor (LF) used to prepare contrived positive samples.

NCT ID: NCT00964834 Terminated - Anthrax Clinical Trials

Ph1 Study of Valortim and Doxycycline in Humans

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of short-term dosing of IV doxycycline when administered concomitantly with IV Valortim in normal healthy human subjects.

NCT ID: NCT00133484 Terminated - Clinical trials for Bacillus Anthracis (Anthrax)

UMD rPA Regimen Trial in Adults

Start date: n/a
Phase: Phase 2
Study type: Interventional

Objectives are: To confirm the safety and tolerability of 2-dose regimens of 100 g rPA vaccines (3 products) administered by the intramuscular (IM) route to healthy adults.To describe the immunologic responses to 2-dose regimens of 3 rPA vaccines and to compare the responses to those following administration of Anthrax Vaccine Adsorbed (AVA or BioThraxTM), the currently available vaccine. The primary immunologic outcome is the proportion of volunteers in each group that mounts an antibody response (defined as a 4-fold or greater increase from pre-vaccination to post-vaccination of anti-rPA IgG antibody with a minimal concentration of 10 µg/ml as measured by ELISA). Secondary outcomes are time to peak response and GMC of anti-PA antibody at peak for each group. In addition, the following immunologic assays will be performed: toxin neutralization assay, oral fluid ELISA, antibody avidity, IgG subclasses, and B-cell memory,T-cell memory and effector subpopulations.